GSK today announced results from BLISS-SC, a 52-week study for BENLYSTA (belimumab) for subcutaneous use (SC) in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) ...

GSK today announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These results ...

The FDA approval was supported by data from the BLISS-SC Phase 3 study (n>800) in patients with active SLE. GlaxoSmithKline announced that the Food and Drug Administration (FDA) has approved Benlysta ...

The 200mg single-dose prefilled autoinjector allows pediatric patients to receive SLE treatment at home via SC administration. The Food and Drug Administration (FDA) has approved Benlysta (belimumab) ...

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive ...

LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a self-injectable formulation of Benlysta for patients with systemic lupus erythematosus, ...

San Francisco and London — On Saturday, Nov. 7, GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These ...

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive ...

SAN FRANCISCO and LONDON, Nov. 10, 2015 /PRNewswire/ -- On Saturday, Nov. 7, GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic ...